Second cancers and causes of death in patients with testicular cancer in Sweden.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
19
11
2018
accepted:
12
03
2019
entrez:
29
3
2019
pubmed:
29
3
2019
medline:
18
12
2019
Statut:
epublish
Résumé
While treatment for testicular cancer (TC) has become standardized after the 1980s with an associated significant improvement in patient survival, this has been accompanied by an increased risk of second primary cancers (SPCs). Patients were identified from the Swedish Cancer Registry spanning the years from 1980 to 2015, including 8788 individuals with primary TC and their SPCs. Relative risks (RRs) for SPC were calculated using the generalized Poisson regression model. SPCs were diagnosed in 9.4% of patients with TC and half of them were late onset cancers not common in the population in their 40s. Overall RR of SPCs (excluding second TC) was 1.30 (95%CI: 1.20-1.40), including high risks for seven solid cancers, non-Hodgkin lymphoma and leukemia. Second TC was the most common SPC and the RR of 17.19 (95%CI: 14.89-19.85) was the highest recorded. Cancers known to be fatal as first primary cancers were also fatal as SPC in TC patients. Survival at 30 years of follow-up was approximately 80% for TC patients without SPC but it decreased to 40% for patients with SPC. The unexpected finding that half of the identified SPCs were typical late onset cancers in the middle-aged population raises concerns that therapy may facilitate premature aging. The risks of SPC are clinically important for the long-term management of TC patients and the high-mortality calls for a future management strategy.
Identifiants
pubmed: 30921367
doi: 10.1371/journal.pone.0214410
pii: PONE-D-18-33236
pmc: PMC6438485
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0214410Commentaires et corrections
Type : CommentIn
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Eur J Cancer. 2014 Mar;50(4):831-9
pubmed: 24369860
Ann Oncol. 2018 Aug 1;29(8):1658-1686
pubmed: 30113631
Sci Rep. 2016 Jul 15;6:29765
pubmed: 27416752
J Clin Oncol. 2013 Dec 20;31(36):4496-503
pubmed: 24248696
Int J Cancer. 2013 Oct 15;133(8):1900-4
pubmed: 23580254
Acta Oncol. 2018 Apr;57(4):440-455
pubmed: 29226751
J Clin Oncol. 2017 May 10;35(14):1584-1590
pubmed: 28384078
Acta Oncol. 1997;36(5):465-9
pubmed: 9292741
BJU Int. 2012 Oct;110(8):1102-9
pubmed: 22429248
JAMA Oncol. 2016 Dec 1;2(12):1624-1627
pubmed: 27711914
Cancer. 2017 Nov 1;123(21):4207-4214
pubmed: 28654149
J Clin Oncol. 2014 Oct 1;32(28):3085-92
pubmed: 25024068
Cancer. 2015 May 15;121(10):1540-7
pubmed: 25529481
J Cancer Res Clin Oncol. 2005 Apr;131(4):255-60
pubmed: 15627215
Lancet. 2016 Apr 23;387(10029):1762-74
pubmed: 26651223
Epidemiology. 1996 Jan;7(1):14-9
pubmed: 8664395
Ann Oncol. 2010 Jul;21(7):1546-51
pubmed: 20019089
J Clin Oncol. 2013 Oct 20;31(30):3807-14
pubmed: 24043737
Int J Cancer. 2010 May 15;126(10):2259-67
pubmed: 19642094
J Natl Cancer Inst. 2005 Sep 21;97(18):1354-65
pubmed: 16174857
Horm Res Paediatr. 2016;86(4):240-246
pubmed: 26871895
Cancer Epidemiol Biomarkers Prev. 2016 May;25(5):773-9
pubmed: 26908435
Ann Oncol. 2017 Nov 1;28(11):2670-2679
pubmed: 29045502
Semin Oncol. 2016 Oct;43(5):575-581
pubmed: 27899190
Int J Cancer. 2012 Nov 1;131(9):2085-93
pubmed: 22307919
J Clin Oncol. 2008 Apr 10;26(11):1850-7
pubmed: 18347006
J Clin Oncol. 2007 Oct 1;25(28):4370-8
pubmed: 17906202
Adv Urol. 2018 Feb 18;2018:8671832
pubmed: 29670654
Int J Cancer. 2006 Jun 15;118(12):3099-111
pubmed: 16395710
J Clin Oncol. 2018 Aug 20;36(24):2504-2513
pubmed: 29989856
Ann Oncol. 2013 Feb;24(2):508-13
pubmed: 23110807
IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt A):1-401
pubmed: 23189749